Expansion Opportunity Hovione is embarking on a multi hundred million euro expansion in Seixal, Portugal with a new medicines manufacturing unit opening in 2027. This signals capacity growth and potential demand for contract manufacturing services, equipment sourcing, and process validation partnerships to support the new facility and related supply chain needs.

Integrated CDMO Capabilities As a full life cycle CDMO with expertise in drug substances, intermediates, and products, Hovione offers end to end development and manufacturing. This presents opportunities to position complementary services such as analytical testing, formulation optimization, and scalable spray drying and continuous tableting collaborations for new and existing partners.

Tech-Forward Partnerships Hovione highlights advanced technologies like Spray Drying and Continuous Tableting and employs BPMN, SCADA, SAP and modern analytics. Sales opportunities exist in integrating clients’ processes with Hovione’s specialized tech platforms to accelerate scale up, improve quality, and ensure robust manufacturing execution.

Global Reach With 2600+ employees across Europe, the USA and Asia, Hovione has a global footprint suitable for multinational partnerships. This enables new business development efforts to target regional biotechs and pharma companies seeking nearshore or offshore manufacturing capabilities aligned with diverse regulatory environments.

Leadership Continuity Leadership under CEO Jean-Luc Herbeaux since 2022 and sustained strategic investments indicate stability and a long-term growth agenda. This can be leveraged to build long-term collaboration and co-development deals, particularly for long-cycle projects that require consistent leadership and ongoing capacity expansion.